SOURCE: BioPharmetics, Inc.

June 26, 2006 09:14 ET

BioPharmetics, Inc. Secures Private Label Manufacturing Deal

Toma® Nail Polish to Be Used for Prescription Colored Fungicidal Nail Polish

NORTH HOLLYWOOD, CA -- (MARKET WIRE) -- June 26, 2006 -- BioPharmetics, Inc. (PINKSHEETS: BPMT) announced the company has secured a six-figure private label contract to supply Toma® nail lacquer to be used in an anti-fungal nail polish sold directly to podiatric physicians throughout the U.S. through a private company based in Texas.

"We're extremely proud this company, who has requested to remain anonymous, has chosen Toma® over our competitors. It speaks highly of the quality that Toma® has made for itself in the lacquer industry. According to company statistics, over 35 million Americans are affected with nail fungus and now there's a product that will both treat and hide," stated Paul D. Lisenby, CEO of BioPharmetics, Inc. Mr. Lisenby further states, "This adds another six-figure account to our company and helps us continue on our path of growth as we strive to move to the OTCBB in the next few months."

For more information about all of BioPharmetics, Inc. products, please visit the website at

About BioPharmetics, Inc. (PINKSHEETS: BPMT)

BioPharmetics, Inc. is a manufacturer and distributor of quality pharmaceutical, cosmetic, and anti-aging products. The company has three divisions: biotechnology, pharmaceuticals, and cosmetics/cosmeceuticals, working in unison to develop, manufacture, and distribute, high-quality products in the retail, wholesale, and professional markets. Brands currently offered include Toma™, Isseo™, Molo Africa™, Micha™, and Natural Angel™. BioPharmetics, Inc. also private labels many brands of cosmetics and cosmeceuticals for salons and retail stores as well as compounding specialized prescriptions for doctors nationwide.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.

Contact Information

  • Contact:
    FutureTechIR for BioPharmetics
    Investor Relations
    (817) 812-2105 or
    (727) 417-9338